FDA says Ozempic shortage is over, chilling boom in off-brand versions
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Ozempic and Wegovy officially moved off FDA’s drug shortage list
Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
Ozempic and Wegovy are no longer in shortage, FDA says
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...
Yearslong shortage of popular weight-loss and diabetes drugs is resolved, FDA says
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...
FierceBiotech3d
Ascletis' swift surge into obesity continues with competitive oral GLP-1 data
Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...
Semaglutide Side Effects: Is It Safe? What You Need To Know
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
Novo Nordisk: Dips Like These Come Once Every Few Years
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
BioSpace11d
Lilly Signs Back-to-Back Deals in MASH, Cancer
Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...
Insider Monkey14d
13 Best Dividend Growth Stocks With 10%+ Yearly Increases
In Q4 2024, the company saw a 45% increase in revenue, reaching $13.53 billion, driven by strong volume growth from Mounjaro and Zepbound. Earnings per share (EPS) for the quarter doubled ...
Knowridge15d
Obesity drug prescriptions are rising strongly
By early 2024, this number had nearly doubled to 1.5 million per month ... name Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound). Among these, phentermine was prescribed the most ...